Related Experiment Videos
Inhaled tiotropium for stable chronic obstructive pulmonary disease
R G Barr1, J Bourbeau, C A Camargo
1Division of General Medicine, PH-9 East Room 105, Columbia-Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA. rgb9@columbia.edu
The Cochrane Database of Systematic Reviews
|April 23, 2005
Summary
Tiotropium significantly reduces exacerbations and hospitalizations in chronic obstructive pulmonary disease (COPD) patients compared to placebo and ipratropium. This anticholinergic therapy also improves quality of life and lung function.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Tiotropium is a novel anticholinergic for COPD, offering once-daily dosing and receptor selectivity.
- It differs functionally from ipratropium in its muscarinic receptor subtype selectivity.
Purpose of the Study:
- To assess tiotropium's efficacy in stable COPD.
- Key endpoints include exacerbations, hospitalizations, symptom scores, and pulmonary function.
- Comparisons were made against placebo and other bronchodilators.
Main Methods:
- Systematic review of randomized controlled trials (RCTs).
- Searches included major databases (CENTRAL, MEDLINE, EMBASE, CINAHL) and journal hand-searching.
- Data extraction and analysis were performed by two independent reviewers.
Main Results:
- Tiotropium reduced COPD exacerbations (OR 0.74) and hospitalizations (OR 0.64) versus placebo/ipratropium.
- Improvements in FEV1 and FVC were observed compared to placebo, ipratropium, and long-acting beta-agonists.
- Dry mouth was a reported side effect.
Conclusions:
- Tiotropium effectively reduces COPD exacerbations and hospitalizations.
- It improves quality of life and symptom scores in moderate to severe COPD.
- Further research is needed on long-term effects and comparisons with other treatments.